Jain Global’s Orchestra BioMed OBIO Stock Holding History

Jain Global’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-24,462	Closed	-$65.6K	–	1361
2025 Q2	$65.6K	Buy	+24,462	New	+$71.4K	﹤0.01%	1075

Other funds holding OBIO

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jain Global's OBIO Position: Q3 2025 in Review

Jain Global sold out of Orchestra BioMed (OBIO) in Q3 2025, closing a stake of 24,462 shares — an estimated $65.6K sold.

Jain Global first reported a position in OBIO in Q2 2025 and held it in 1 quarter. The position peaked at $65.6K in Q2 2025. 52 funds tracked by Wall St. Rank hold OBIO as of Q3 2025.

Jain Global reported no remaining Orchestra BioMed position as of Q3 2025 after selling out during the quarter.
Jain Global sold 24,462 Orchestra BioMed shares in Q3 2025, an estimated $65.6K.
Jain Global first reported a position in Orchestra BioMed in Q2 2025 and held it in 1 quarter.
Jain Global's Orchestra BioMed position peaked at $65.6K in Q2 2025.
52 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2025.

Based on Jain Global's 13F filing for Q3 2025, filed 14 Nov 2025.